Jordan V C, Assikis V J
Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611, USA.
Clin Cancer Res. 1995 May;1(5):467-72.
During the past 5 years, a number of case reports and clinical trial results have associated tamoxifen therapy with an increased incidence of endometrial carcinoma. A review of the literature shows that there are over 200 cases of endometrial carcinoma reported in tamoxifen-treated women. Most cases are Stage I (82%), grade 1-2 disease (80%), which is consistent with the Surveillance Epidemiology and End Results Reporting data of 74 and 79% for Stage I and grade 1-2 endometrial carcinoma. We conclude that there is a modest increase in endometrial carcinoma incidence during tamoxifen therapy (i.e., 2/1000 tamoxifen treated women per year versus 1/1000 women per year for Surveillance Epidemiology and End Results Reporting), that there is no strong association with duration of therapy, and that tamoxifen is not associated with a high-grade, poor prognosis disease. The benefits of tamoxifen in lives saved exceeds the incidence of endometrial carcinoma.
在过去5年中，多项病例报告和临床试验结果表明，他莫昔芬治疗与子宫内膜癌发病率增加有关。文献综述显示，接受他莫昔芬治疗的女性中有200多例子宫内膜癌病例报告。大多数病例为I期（82%），1-2级疾病（80%），这与监测、流行病学和最终结果报告中I期和1-2级子宫内膜癌分别为74%和79%的数据一致。我们得出结论，他莫昔芬治疗期间子宫内膜癌发病率有适度增加（即每年每1000名接受他莫昔芬治疗的女性中有2例，而监测、流行病学和最终结果报告为每年每1000名女性中有1例），与治疗持续时间没有密切关联，且他莫昔芬与高级别、预后不良的疾病无关。他莫昔芬在挽救生命方面的益处超过了子宫内膜癌的发病率。
